LATEST TRIALS

  • Hematological Malignancies
    A phase 1/2 dose escalation safety, pharmacokinetic and efficacy study of multiple intravenous administration of a human monoclonal antibody (SAR6509848) against CD38 in patients with selected CD38+ hematological malignancies
  • Melanoma
    VLX1570 and low-dose dexametasone in relapsed or replaised and refractory multiple myeloma: A clinical and correlative phase 1/2 study
  • Melanoma
    A phase 1b/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab (MK-3475) for treatment of unresectable stage IIIB to IVM1c melanoma (MASTERKEY-265)

NORDIC COOPERATION

Norway Norway Sweden Finland Aarhus Herlev Copenhagen